Treatment of Depression Becomes More Affordable

Depressive Disorders affect approximately 18.8 million Americans each year. Of this, approximately 80% of suffers do not seek treatment with cost of care as a primary factor.  With the FDA’s approval of the generic depressive medication, Venlafaxine, the treatment window for depression has widened and is now made more available to patients who may otherwise not seek treatment. When considering treatment options, consult your physician regarding the use of the FDA approved generic of Effexor, Venlafaxine. With appropriate dosing, monitoring of contraindications and knowledge of side effects, Venlafaxine may provide the solution to relieving major depressive symptoms such as fatigue, helplessness, hopelessness, suicidal ideation and sadness. 

Venlafaxine, a product of TEVA, was designed in the treatment of major depressive disorders through its ability to inhibit the body’s re-uptake of norepinephrine. As a generic drug for the treatment of depression, Venlafaxine impacts and improves major depressive disorder through its ability control, regulate and contribute to hormonal influctuations commonly seen in the depressed patient. Improvement of depressive symptoms is most commonly progressive but can be seen in as little as two weeks and, in some cases, without requiring additional treatment or mental health intervention.